Russia ensuring rights of workers at FIFA World Cup construction sites — officialSport May 26, 3:08
Russian emergencies minister arrives in flood-hit southern RussiaWorld May 26, 2:56
NATO to join anti-IS coalition but unlikely to engage in combat — chiefWorld May 26, 0:23
Son of LUKOIL corporation co-owner tops list of Russia's richest legateesBusiness & Economy May 26, 0:23
Russian Foreign Ministry: OPCW not rushing to investigate chemical incident in SyriaRussian Politics & Diplomacy May 25, 21:28
Russia’s legendary barque Kruzenshtern calls at Belgian portSociety & Culture May 25, 20:26
OPEC and non-OPEC countries to develop cooperation outside Vienna agreementBusiness & Economy May 25, 19:44
Russia squared-off with Western media blitz to smear World Cup preparationsSport May 25, 19:35
NATO seeks to continue and expand dialogue with RussiaWorld May 25, 19:01
TOKYO, May 22, 2013 /PRNewswire/ -- Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a subsidiary of Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), announced on May 22 the actions that Ranbaxy has taken in recent years to address past conduct under prior management.
Daiichi Sankyo continues to support Ranbaxy in its efforts to address and correct the conduct of the past which led to the investigations by the U.S. Department of Justice ("DOJ") and the U.S. Food and Drug Administration ("USFDA"). These efforts include significant changes to Ranbaxy's management, culture, operations and compliance.
Daiichi Sankyo believes that certain former shareholders of Ranbaxy concealed and misrepresented critical information concerning the U.S. DOJ and FDA investigations. Daiichi Sankyo is currently pursuing its available legal remedies and cannot comment further on the subject at this time.
About Daiichi Sankyo Co., Ltd.
Listed: Code No.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges
President and CEO: Joji Nakayama
Noriaki Ishida, Corporate Officer & Vice President Corporate Communications Department Daiichi Sankyo Co., Ltd.